SCHEMBL4173085

SCHEMBL4173085

Brc1ccc(-c2nnc(-c3ccccc3NCc3ccc4[nH]ncc4c3)[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.50
FLT1 P17948 2/20 0.46
CDK2 P24941 2/20 0.43
CDC7 O00311 1/20 0.43
CCNE1 P24864 1/20 0.43
DBF4 Q9UBU7 1/20 0.43
TRPA1 O75762 5/20 0.42
ROCK2 O75116 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
PRKACA P17612 2/20 0.41
RPS6KB1 P23443 2/20 0.41
PRKX P51817 2/20 0.41
ROCK1 Q13464 2/20 0.41
RPS6KA5 O75582 1/20 0.41
PRKG2 Q13237 1/20 0.41
SGK2 Q9HBY8 1/20 0.41
MAPK1 P28482 3/20 0.41
GSK3B P49841 2/20 0.41
CLK2 P49760 2/20 0.41
DYRK1A Q13627 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4181588 0.92 KDR (0.46) KDRFLT1CDK2CLK4CLK2
SCHEMBL4168403 0.82 ROCK2 (0.47) KDRFLT1ROCK2CLK4ROCK1
SCHEMBL4166211 0.74 KDR (0.43) KDRFLT1ROCK2MAPK1
SCHEMBL4188190 0.74 KDR (0.50) KDRFLT1CDK2ROCK2CLK4
SCHEMBL4177098 0.73 KDR (0.76) KDRFLT1ROCK2MEN1KMT2A
SCHEMBL4174883 0.73 KDR (0.69) KDRFLT1MEN1KMT2A
SCHEMBL4174895 0.71 KDR (0.48) KDRFLT1CDK2CDC7CCNE1
SCHEMBL13122080 0.69 ROCK2 (0.67) CDK2CDC7CCNE1DBF4ROCK2
SCHEMBL13950020 0.68 KDM4E (0.35) MEN1KMT2A
SCHEMBL4177417 0.67 ADRA2C (0.59) KDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL KDR 3284/4885FLT1 3408/4885CDK2 53/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL KDR 3284/4885FLT1 3408/4885CDK2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.